Company History
2025
-
07
IND approval for Project 203 in Korea
-
06
Project 201, Project 202 Interim data publication (ICML 2025)
-
02
Poseltinib for PCNSL, orphan drug designation in Korea
2024
-
09
IND approval for Project 202 in Korea
-
06
Project 201 2nd Interim data publication (ASCO 2024)
-
04
In-license agreement of Poseltinib
-
03
Company name change from Genome Opinion to NOBO Medicine
2023
-
12
Emricasan acquisition
-
09
Establishment of the clonal hematopoiesis mouse model
-
06
Project 201 1st Interim data publication (EHA 2023)
-
05
Optimization of NOBO_VERSE database
2021
-
10
Initiation of Project 201 with Hanmi Pharmaceuticals
2020
-
12
Strategic partnership with Yuhan Pharmaceuticals
2019
-
09
NOBO_VERSE database development initiation
-
07
Collaborative research with SNUH Gangnam center
-
05
Series A closed
2017
-
10
Corporate establishment
